Clinical Characteristics of Patients With Advanced Hepatocellular Carcinoma Who Transitioned to Subsequent Therapies Following Systemic Therapy
Cancer Medicine · 2026
DOI: 10.1002/cam4.71616 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Kenji Imai und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology/Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aim
This study aimed to clarify the clinical characteristics of patients with advanced hepatocellular carcinoma (HCC) who transitioned to subsequent therapies following systemic therapy (ST).
Methods
In total, 136 patients with unresectable HCC (26 hepatitis B, 47 hepatitis C and 63 others) receiving first‐line ST, including 31 patients treated with immune checkpoint inhibitors (ICIs), were enrolled. Clinical characteristics and adverse events observed during treatment, as well as overall survival (OS), progression‐free survival and post progression survival (PPS), were compared between patients who transitioned to subsequent therapies (2nd therapy group, n = 66) and those who did not (non‐2nd therapy group, n = 70).
Results
Significant differences between the two groups were observed in OS (29.3 vs. 10.7 months, p < 0.001), PPS (11.3 vs. 2.9 months, p < 0.001), ALBI score (−2.48 vs. −2.34, p = 0.018), treatment with/without ICIs (24/42 vs. 7/63, p < 0.001), TNM stage (II/III/IVA/IVB; 15/26/7/18 vs. 3/27/10/30, p = 0.008) and the adverse events of appetite loss ( p = 0.009) and proteinuria ( p = 0.006). A favourable ALBI score ( p = 0.005), treatment with ICIs ( p = 0.002) and earlier TNM stage ( p = 0.027) identified by logistic regression analysis and TNM stage II in men and prothrombin time ≥ 105% in women by classification tree analysis were found to be associated with a higher likelihood of transitioning to subsequent therapies.
Conclusions
Initiating systemic therapy, including ICIs, before clinical stage progression and preserving the hepatic reserve is crucial for ensuring a smooth transition to subsequent therapies. Registry and the Registration No. of the Study/Trial N/A.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology/Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.
ORCID-Profile: Kenji Imai, Shinji Unome, Takao Miwa, Tatsunori Hanai, Yohei Shirakami
Zitieren
APA
Imai, K., Takai, K., Aiba, M., Unome, S., Miwa, T., Hanai, T., Sakai, H., Shirakami, Y., Suetsugu, A., & Shimizu, M. (2026). Clinical Characteristics of Patients With Advanced Hepatocellular Carcinoma Who Transitioned to Subsequent Therapies Following Systemic Therapy. Cancer Medicine. https://doi.org/10.1002/cam4.71616
Vancouver
Imai K, Takai K, Aiba M, Unome S, Miwa T, Hanai T, et al. Clinical Characteristics of Patients With Advanced Hepatocellular Carcinoma Who Transitioned to Subsequent Therapies Following Systemic Therapy. Cancer Medicine. 2026. doi:10.1002/cam4.71616
BibTeX
@article{Imai2026,
author = {Imai, Kenji and Takai, Koji and Aiba, Masashi and Unome, Shinji and Miwa, Takao and Hanai, Tatsunori and Sakai, Hiroyasu and Shirakami, Yohei and Suetsugu, Atsushi and Shimizu, Masahito},
title = {Clinical Characteristics of Patients With Advanced Hepatocellular Carcinoma Who Transitioned to Subsequent Therapies Following Systemic Therapy},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.71616}
}
EUVIMED